{
  "metadata": {
    "case_id": 94,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T19:34:32.772147",
    "total_alignments": 5,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/94_NCT03408730.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/94_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.identificationModule.secondaryIdInfos",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          1.0
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 1.0,
          "status": "matched",
          "ref_item": {
            "id": "2017-001820-22",
            "type": "EUDRACT_NUMBER"
          },
          "pred_item": {
            "id": "2017-001820-22",
            "type": "EUDRACT_NUMBER",
            "domain": "EU Clinical Trials Register",
            "link": null
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.93,
          0.86,
          0.92,
          0.7
        ],
        [
          0.84,
          0.93,
          0.82,
          0.78
        ],
        [
          0.92,
          0.84,
          0.94,
          0.82
        ],
        [
          0.4,
          0.7,
          0.5,
          0.93
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "label": "Sci-B-Vac Lot A Hep B Vaccination",
            "type": "EXPERIMENTAL",
            "description": "Sci-B-Vac Lot A Hepatitis B Vaccination",
            "interventionNames": [
              "Biological: Hepatitis B Vaccination"
            ]
          },
          "pred_item": {
            "label": "3A-HBV Lot A",
            "type": "EXPERIMENTAL",
            "description": "Participants received the 3-antigen hepatitis B virus vaccine (Sci-B-Vac) from manufacturing lot A. Each participant was administered a 1-mL intramuscular dose containing 10 μg of pre-S1/pre-S2/S virus-like particle adsorbed on aluminum hydroxide on days 0, 28, and 168.",
            "interventionNames": [
              "3-antigen hepatitis B virus vaccine (3A-HBV)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "label": "Sci-B-Vac Lot B Hep B Vaccination",
            "type": "EXPERIMENTAL",
            "description": "Sci-B-Vac Lot B Hepatitis B Vaccination",
            "interventionNames": [
              "Biological: Hepatitis B Vaccination"
            ]
          },
          "pred_item": {
            "label": "3A-HBV Lot B",
            "type": "EXPERIMENTAL",
            "description": "Participants received the 3-antigen hepatitis B virus vaccine (Sci-B-Vac) from manufacturing lot B. Each participant was administered a 1-mL intramuscular dose containing 10 μg of pre-S1/pre-S2/S virus-like particle adsorbed on aluminum hydroxide on days 0, 28, and 168.",
            "interventionNames": [
              "3-antigen hepatitis B virus vaccine (3A-HBV)"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "label": "Sci-B-Vac Lot C Hep B Vaccination",
            "type": "EXPERIMENTAL",
            "description": "Sci-B-Vac Lot C Hepatitis B Vaccination",
            "interventionNames": [
              "Biological: Hepatitis B Vaccination"
            ]
          },
          "pred_item": {
            "label": "3A-HBV Lot C",
            "type": "EXPERIMENTAL",
            "description": "Participants received the 3-antigen hepatitis B virus vaccine (Sci-B-Vac) from manufacturing lot C. Each participant was administered a 1-mL intramuscular dose containing 10 μg of pre-S1/pre-S2/S virus-like particle adsorbed on aluminum hydroxide on days 0, 28, and 168.",
            "interventionNames": [
              "3-antigen hepatitis B virus vaccine (3A-HBV)"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 3,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "label": "Comparator: ENGERIX-B Hep B Vaccination",
            "type": "ACTIVE_COMPARATOR",
            "description": "Active Comparator: ENGERIX-B Hepatitis B Vaccination",
            "interventionNames": [
              "Biological: Hepatitis B Vaccination"
            ]
          },
          "pred_item": {
            "label": "1A-HBV",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants received the comparator single-antigen hepatitis B virus vaccine (Engerix-B or equivalent). Each participant was administered a 1-mL intramuscular dose containing 20 μg of HBsAg-S adsorbed onto 0.5 mg of aluminum hydroxide on days 0, 28, and 168.",
            "interventionNames": [
              "Single-antigen hepatitis B virus vaccine (1A-HBV)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.9,
          0.93
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "Hepatitis B Vaccination",
            "description": "Hepatitis B Vaccination",
            "armGroupLabels": [
              "Comparator: ENGERIX-B Hep B Vaccination",
              "Sci-B-Vac Lot A Hep B Vaccination",
              "Sci-B-Vac Lot B Hep B Vaccination",
              "Sci-B-Vac Lot C Hep B Vaccination"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "Single-antigen hepatitis B virus vaccine (1A-HBV)",
            "description": "Conventional yeast-derived hepatitis B vaccine (e.g., Engerix-B), provided as 1-mL vials containing 20 μg of HBsAg-S adsorbed onto 0.5 mg of Al3+ as aluminum hydroxide adjuvant. Administered intramuscularly on days 0, 28, and 168 as the active comparator.",
            "armGroupLabels": [
              "1A-HBV"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.99
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.99,
          "status": "matched",
          "ref_item": {
            "measure": "Geometric Mean Concentration (GMC) of Anti-HBs at Day 196 for Lot-to-Lot Consistency (Per Protocol Set 1)",
            "description": "To demonstrate the manufacturing equivalence, in terms of immunogenicity, as measured by GMC of antibodies, of 3 independent consecutive lots of the Sci-B-Vac® 4 weeks after the third vaccination. Lot-to-lot manufacturing consistency of Sci-B-Vac® is demonstrated if the 95% CIs of the adjusted anti-HBs GMC ratios between lots are within the pre-specified range of \\[0.67, 1.5\\].",
            "timeFrame": "4 weeks after third vaccination (Study Day 196)"
          },
          "pred_item": {
            "measure": "Manufacturing equivalence of 3A-HBV vaccine lots based on geometric mean concentration of anti-HBs",
            "description": "Lot-to-lot consistency (manufacturing equivalence) of three consecutively manufactured 3-antigen HBV (3A-HBV) vaccine lots, assessed by the geometric mean concentration (GMC) of serum hepatitis B surface antibodies (anti-HBs) and the pairwise GMC ratios between lots, with 95% confidence intervals required to fall within 0.67 to 1.50.",
            "timeFrame": "Day 196 (4 weeks after the third vaccination)"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.96,
          0.18
        ],
        [
          0.1,
          0.86
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Seroprotection Rate (SPR) of Anti-HBs at Day 196 for Sci-B-Vac® Compared to Day 196 for Engerix-B® (Per Protocol Set 2)",
            "description": "The difference in proportions \\[SPR(Sci-B-Vac®)-SPR(Engerix-B®)\\] and two-sided 95% CIs were summarized. If the lower bound of the 95% CI was \\> 5%, Sci-B-Vac® was to be declared non-inferior to Engerix-B®",
            "timeFrame": "4 weeks after third vaccination (Study Day 196)"
          },
          "pred_item": {
            "measure": "Seroprotection rate after 3-dose regimen of 3A-HBV vs 1A-HBV",
            "description": "Noninferiority of seroprotection rate (SPR) of pooled 3A-HBV compared with single-antigen HBV (1A-HBV), where seroprotection is defined as an anti-HBs concentration of at least 10 mIU/mL in serum; noninferiority met if the lower bound of the 2-sided 95% confidence interval of (SPR 3A-HBV minus SPR 1A-HBV) is greater than −5%.",
            "timeFrame": "Day 196 (4 weeks after the third vaccination)"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs)",
            "description": "Analysis of local and systemic solicited adverse events with an interval of onset of Day 1 to Day 7 after any vaccination with either Sci-B-Vac® or Engerix-B®, in adults ≥18 years old.",
            "timeFrame": "Day of vaccine administration and six subsequent days"
          },
          "pred_item": {
            "measure": "Safety and reactogenicity of 3A-HBV compared with 1A-HBV",
            "description": "Incidence, nature, severity, and duration of solicited local and systemic adverse events within 7 days after any vaccination; unsolicited adverse events within 28 days after any vaccination; serious adverse events and vaccine discontinuations due to adverse events over the entire study period, in participants who received at least one vaccine dose.",
            "timeFrame": "From first vaccination (Day 0) through Day 336, with specified windows: solicited AEs Day 1–7 after each vaccination, unsolicited AEs Day 1–28 after each vaccination, SAEs Day 1–336"
          }
        }
      ]
    }
  ]
}